ClinicalTrials.gg
Not yet recruitingNCT07943091Updated Nov 17, 2026

A Study of LY3945262 in Healthy Participants

A Phase 1 interventional study of LY3945262 and Placebo in Healthy Volunteers, sponsored by Eli Lilly and Company. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate how well LY3945262 is tolerated, what side effects may occur, and how much LY3945262 gets into the bloodstream and how long it takes the body to remove it in healthy participants. The study will also compare how LY3945262 gets into the bloodstream when administered in different ways.

This study will last approximately 8 weeks and may include up to 4 visits.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and (ECG).

    • To qualify as Japanese for the purpose of this study, the participant must be first generation Japanese, defined as the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan.
    • To qualify as Chinese for the purpose of this study, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participant's biological grandparents must be of exclusive Chinese descent, and must have been born in China.
  • Individuals assigned male at birth (AMAB) and individuals not of (INOCBP) may participate in this trial. Individuals of childbearing potential (IOCBP) are excluded from this trial.
  • Have a body weight of at least 50 kilogram (kg) and within the range of 18.5 to less than or equal to 35 kilogram per square meter (kg/m²).

Exclusion criteria

Exclusion Criteria:

  • Have a significant history, or current evidence, of any of the following types of disorders that could significantly alter the absorption, metabolism, or elimination of drugs; pose a risk during administration of the product; or interfere with data interpretation:

    • cardiovascular
    • respiratory, including bronchospasm or bronchial asthma, or chronic obstructive airways disease
    • hepatic
    • renal
    • gastrointestinal
    • endocrine, such as diabetes, acromegaly, Cushing syndrome, hyper- or hypothyroidism (Including subclinical hypothyroidism measured using thyroid stimulating hormone), or hyperaldosteronism
    • hematological
  • Have a history of hypertension, or a blood pressure (BP) reading that is abnormal for the population
  • Have known or ongoing psychiatric disorders.
  • Have used or intend to use over the counter or herbal supplements (for example, St. John's wort) or prescription medication within 14 days or 5 half-lives, whichever is longer, before initial dosing or during the study. If this situation arises, inclusion of an otherwise suitable participant may be at the discretion of the investigator and sponsor.
  • Regularly use known drugs of abuse and/or show positive findings on drug screening.
  • Are currently enrolled in any other clinical trial involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have participated, within the past 30 days, in a clinical study involving an investigational product with a short half-life. If the previous investigational product has a long half-life, 3 months or 5 half-lives, whichever is longer, should have passed.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    LY3945262 Part A (SAD)

    Single Ascending Doses (SAD) of LY3945262 administered orally

    Drug: LY3945262

  • Placebo comparator
    Placebo Part A (SAD)

    Placebo administered orally

    Drug: Placebo

  • Experimental
    LY3945262 Part B (MAD)

    Multiple Ascending Doses (MAD) of LY3945262 administered orally. Participants will also receive 2 doses of Midazolam (one before and one with LY3945262) administered orally.

    Drug: LY3945262 · Drug: Midazolam

  • Placebo comparator
    Placebo Part B (MAD)

    Placebo administered orally. Participants will also receive 2 doses of Midazolam (one before and one with placebo) administered orally.

    Drug: Placebo · Drug: Midazolam

  • Experimental
    LY3945262 Part C (Test)

    LY3945262 tablet formulation administered orally

    Drug: LY3945262

  • Active comparator
    LY3945262 Part C (Reference)

    LY3945262 capsule formulation administered orally

    Drug: LY3945262

Interventions

  • DrugLY3945262

    Administered Orally

  • DrugPlacebo

    Administered Orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline to Study Completion (Up to 8 weeks)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3945262

    Time frame: Baseline to Study Completion (Up to 8 Weeks)

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY3945262

    Time frame: Baseline to Study Completion (Up to 8 weeks)

07

Study locations

2 sites
  • Collaborative Neuroscience Network - CNS
    Los Alamitos, California 90720, United States
    • · Contact844-424-9494
    • Steven Reynolds · Principal investigator
  • ICON Early Phase Services
    San Antonio, Texas 78232, United States
    • · Contact210-283-4500
    • Chinonye Ogbonnaya-Odor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Sep 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943091
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion